Response | SVR12 (N = 1358) | Heterogeneity | Pb-value | Studies | ||
---|---|---|---|---|---|---|
 | Total, n/N | Rate (95%CI) | I2(%) | P a |  |  |
Overall | 1296/1358 | 96.3 (95.1–97.4) | 42 | 0.08 |  | 10 |
By the different duration of treatment | 0.9237 | Â | ||||
 12 weeks | 394/415 | 96.2 (92.6–98.8) | 41 | 0.13 |  | 6 |
 24 weeks | 52/55 | 96.6 (82.5–100.0) | 65 | 0.09 |  | 2 |
By regimens | 0.8563 | Â | ||||
 OBV/PTV/r ± DSV ± RBV | 811/850 | 96.4 (94.8–97.7) | 25 | 0.21 |  | 10 |
 OBV/PTV/r ± RBV | 152/159 | 98.9 (95.3–100.0) | 0.0 | 0.99 |  | 3 |
By genotypes | 0.8424 | Â | ||||
 1 | 1025/1076 | 96.2 (94.8–97.4) | 38 | 0.13 |  | 8 |
 4 | 149/156 | 98.8 (95.1–100.0) | 0 | 0.99 |  | 3 |
By treatment history | 0.8281 | Â | ||||
 TN patients | 423/440 | 96.8 (94.8–98.5) | 41 | 0.15 |  | 5 |
 TE patients | 273/285 | 98.9 (96.4–100.0) | 50 | 0.09 |  | 5 |
By the presence or absence of cirrhosis | 0.3887 | Â | ||||
 Cirrhosis | 218/230 | 97.8 (94.6–99.8) | 43 | 0.12 |  | 6 |
 Non-cirrhosis | 899/935 | 96.7 (95.3–97.8) | 20 | 0.28 |  | 6 |